CD4-positive T cell activation

CD4-positive T cell activation is the process by which naive CD4+ T cells are stimulated to become active participants in the immune response. This activation requires antigen recognition via the T cell receptor (TCR) and MHC class II complex, co-stimulatory signals such as CD28-CD80/86 interaction, and a specific cytokine environment. Successful activation leads to proliferation and differentiation into various effector subtypes (Th1, Th2, Th17, Tregs) with specialized roles in orchestrating immune responses. Dysregulation of this process can result in immunodeficiency or autoimmune disease.

Drugs targeting CD4+ T cell activation often interfere with T cell receptor signaling, co-stimulation, or cytokine production to suppress or modulate the immune response. Examples include: - Calcineurin inhibitors (cyclosporine, tacrolimus): Block T cell activation by inhibiting calcineurin-dependent NFAT activation. - mTOR inhibitors (sirolimus): Suppress T cell proliferation by inhibiting mTOR. - Co-stimulation blockers (abatacept): Prevent CD28-CD80/86 interaction, inhibiting T cell activation. - Checkpoint inhibitors (anti-CTLA-4, anti-PD-1): Enhance T cell activation by blocking inhibitory signals.